Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 4/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177176 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1176219 | 0.76 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL2308352 | 0.75 | DYRK1A (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1179496 | 0.72 | NPC1 (0.43) | PDE10ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1180003 | 0.72 | DYRK1A (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL4060221 | 0.72 | MAP4K4 (0.46) | MAPT | |
| SCHEMBL14881117 | 0.71 | PDE4B (0.48) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| Bicarbonate SCHEMBL2310949 | 0.70 | CASP3 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL24176371 | 0.69 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1761323 | 0.69 | DGAT1 (0.52) | NPC1MAPTMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394823-B2 | Triazolopyridine compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394823-B2 | Triazolopyridine compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394823-B2 | Triazolopyridine compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110034506-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034506-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034506-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2009126861-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034506-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | PDE10A 2068/4885NPC1 55/4885RAB9A 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.